UY27109A1 - Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b - Google Patents
Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/bInfo
- Publication number
- UY27109A1 UY27109A1 UY27109A UY27109A UY27109A1 UY 27109 A1 UY27109 A1 UY 27109A1 UY 27109 A UY27109 A UY 27109A UY 27109 A UY27109 A UY 27109A UY 27109 A1 UY27109 A1 UY 27109A1
- Authority
- UY
- Uruguay
- Prior art keywords
- antagonists
- quinazolona
- alfa
- derivatives
- adrenergic receptors
- Prior art date
Links
- 108060003345 Adrenergic Receptor Proteins 0.000 title abstract 2
- 102000017910 Adrenergic receptor Human genes 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25933701P | 2001-01-02 | 2001-01-02 | |
| US32526701P | 2001-09-27 | 2001-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY27109A1 true UY27109A1 (es) | 2002-07-31 |
Family
ID=26947245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY27109A UY27109A1 (es) | 2001-01-02 | 2001-12-28 | Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1363899B1 (enExample) |
| JP (1) | JP4031363B2 (enExample) |
| KR (1) | KR100554813B1 (enExample) |
| CN (1) | CN1237060C (enExample) |
| AR (1) | AR035775A1 (enExample) |
| AT (1) | ATE295362T1 (enExample) |
| BR (1) | BR0116662A (enExample) |
| CA (1) | CA2432578C (enExample) |
| DE (1) | DE60110844T2 (enExample) |
| ES (1) | ES2241891T3 (enExample) |
| MX (1) | MXPA03005854A (enExample) |
| PA (1) | PA8536001A1 (enExample) |
| PE (1) | PE20020735A1 (enExample) |
| UY (1) | UY27109A1 (enExample) |
| WO (1) | WO2002053558A1 (enExample) |
| ZA (1) | ZA200305038B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0206033D0 (en) * | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| GB0225908D0 (en) * | 2002-11-06 | 2002-12-11 | Pfizer Ltd | Treatment of female sexual dysfunction |
| WO2005005397A1 (en) * | 2003-07-02 | 2005-01-20 | F. Hoffmann-La Roche Ag | 5-substituted quinazolinone derivatives |
| JP2009513502A (ja) * | 2003-07-02 | 2009-04-02 | エフ．ホフマン−ラ ロシュ アーゲー | アリールアミン置換キナゾリノン化合物 |
| TW200530235A (en) | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
| US7793137B2 (en) | 2004-10-07 | 2010-09-07 | Cisco Technology, Inc. | Redundant power and data in a wired data telecommunincations network |
| FR2870846B1 (fr) | 2004-05-25 | 2006-08-04 | Sanofi Synthelabo | Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique |
| US20060128710A1 (en) * | 2004-12-09 | 2006-06-15 | Chih-Hung Lee | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
| US7297700B2 (en) | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| WO2006119504A2 (en) | 2005-05-04 | 2006-11-09 | Renovis, Inc. | Fused heterocyclic compounds, and compositions and uses thereof |
| US7709468B2 (en) | 2005-09-02 | 2010-05-04 | Abbott Laboratories | Imidazo based heterocycles |
| EP1956001A4 (en) * | 2005-11-24 | 2012-12-26 | Kissei Pharmaceutical | PHARMACEUTICAL PRODUCT FOR USE IN THE TREATMENT OF URETEROLITHIASE |
| CA2682162C (en) | 2007-04-02 | 2016-05-10 | Renovis, Inc. | Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof |
| PL2139334T3 (pl) | 2007-04-17 | 2013-11-29 | Evotec Ag | Skondensowane związki heterocykliczne 2-cyjanofenylu i ich kompozycje i zastosowania |
| US8859538B2 (en) | 2007-06-21 | 2014-10-14 | Cara Therapeutics, Inc. | Uses of substituted imidazoheterocycles |
| EA201000046A1 (ru) | 2007-06-21 | 2011-02-28 | Кара Терапеутикс, Инк. | Замещенные имидазогетероциклы |
| CN101417999A (zh) * | 2007-10-25 | 2009-04-29 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| JO3156B1 (ar) | 2009-07-09 | 2017-09-20 | Novartis Ag | ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا |
| WO2015018797A2 (en) * | 2013-08-05 | 2015-02-12 | Haplogen Gmbh | Antiviral compounds |
| GB201321748D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| SG11201604878XA (en) * | 2013-12-20 | 2016-07-28 | Esteve Labor Dr | Fused imidazolyl derivatives, their preparation and use as medicaments |
| AU2017266911B2 (en) | 2016-05-18 | 2021-09-02 | Array Biopharma, Inc. | KRas G12C inhibitors |
| CN107434786B (zh) * | 2016-05-27 | 2025-11-18 | 广东东阳光药业股份有限公司 | 苯并咪唑化合物及其制备方法 |
| TWI791515B (zh) | 2017-04-24 | 2023-02-11 | 瑞士商諾華公司 | 治療療法 |
| SI3710439T1 (sl) | 2017-11-15 | 2023-06-30 | Mirati Therapeutics, Inc., | Zaviralci mutacije kras g12c |
| US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EP3849538A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3849536A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| HRP20250059T1 (hr) | 2018-09-10 | 2025-03-28 | Mirati Therapeutics, Inc. | Kombinirane terapije |
| EA202190630A1 (ru) | 2018-12-05 | 2021-10-11 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| KR20210146288A (ko) * | 2019-03-01 | 2021-12-03 | 레볼루션 메디슨즈, 인크. | 이환식 헤테로사이클릴 화합물 및 이의 용도 |
| JP7622043B2 (ja) | 2019-08-29 | 2025-01-27 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｄ阻害剤 |
| CA3152025A1 (en) | 2019-09-24 | 2021-04-01 | David BRIERE | Combination therapies |
| CN110950886A (zh) * | 2019-12-13 | 2020-04-03 | 苏州莱克施德药业有限公司 | 一种合成1-甲基-咪唑-2-甲酸甲酯衍生物的方法 |
| EP4076418A4 (en) | 2019-12-20 | 2024-01-24 | Mirati Therapeutics, Inc. | Sos1 inhibitors |
| JP2023540809A (ja) | 2020-09-11 | 2023-09-26 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤の結晶形態 |
| IL303446A (en) | 2020-12-15 | 2023-08-01 | Mirati Therapeutics Inc | Azaquinazoline compounds as PAN-KRas inhibitors |
| WO2022133038A1 (en) | 2020-12-16 | 2022-06-23 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1062357A (en) * | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
| US4044136A (en) * | 1972-09-09 | 1977-08-23 | Pfizer Inc. | Aminoquinazoline therapeutic agents |
| DE2757925A1 (de) * | 1977-12-24 | 1979-06-28 | Bayer Ag | Diazacyclo-1.2.4-benzothiadizine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
| NZ325248A (en) * | 1995-12-23 | 1999-09-29 | Pfizer Res & Dev | Quinoline and quinazoline compounds useful in therapy |
| GB9700504D0 (en) * | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
| WO2000055143A1 (en) * | 1999-03-17 | 2000-09-21 | F. Hoffmann-La Roche Ag | Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators |
-
2001
- 2001-12-17 JP JP2002554677A patent/JP4031363B2/ja not_active Expired - Fee Related
- 2001-12-17 MX MXPA03005854A patent/MXPA03005854A/es active IP Right Grant
- 2001-12-17 CA CA002432578A patent/CA2432578C/en not_active Expired - Fee Related
- 2001-12-17 CN CNB018217133A patent/CN1237060C/zh not_active Expired - Fee Related
- 2001-12-17 DE DE60110844T patent/DE60110844T2/de not_active Expired - Fee Related
- 2001-12-17 EP EP01985417A patent/EP1363899B1/en not_active Expired - Lifetime
- 2001-12-17 WO PCT/EP2001/014885 patent/WO2002053558A1/en not_active Ceased
- 2001-12-17 ES ES01985417T patent/ES2241891T3/es not_active Expired - Lifetime
- 2001-12-17 KR KR1020037008921A patent/KR100554813B1/ko not_active Expired - Fee Related
- 2001-12-17 BR BR0116662-0A patent/BR0116662A/pt not_active IP Right Cessation
- 2001-12-17 AT AT01985417T patent/ATE295362T1/de not_active IP Right Cessation
- 2001-12-27 PE PE2001001308A patent/PE20020735A1/es not_active Application Discontinuation
- 2001-12-27 PA PA20018536001A patent/PA8536001A1/es unknown
- 2001-12-28 AR ARP010106092A patent/AR035775A1/es unknown
- 2001-12-28 UY UY27109A patent/UY27109A1/es not_active Application Discontinuation
-
2003
- 2003-06-28 ZA ZA200305038A patent/ZA200305038B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PA8536001A1 (es) | 2002-08-29 |
| KR100554813B1 (ko) | 2006-02-22 |
| ATE295362T1 (de) | 2005-05-15 |
| ZA200305038B (en) | 2004-09-27 |
| CN1484640A (zh) | 2004-03-24 |
| DE60110844T2 (de) | 2006-01-12 |
| CA2432578A1 (en) | 2002-07-11 |
| KR20030063490A (ko) | 2003-07-28 |
| DE60110844D1 (de) | 2005-06-16 |
| CN1237060C (zh) | 2006-01-18 |
| EP1363899B1 (en) | 2005-05-11 |
| MXPA03005854A (es) | 2003-09-10 |
| ES2241891T3 (es) | 2005-11-01 |
| AR035775A1 (es) | 2004-07-14 |
| JP2004519454A (ja) | 2004-07-02 |
| PE20020735A1 (es) | 2002-08-21 |
| BR0116662A (pt) | 2003-09-23 |
| EP1363899A1 (en) | 2003-11-26 |
| CA2432578C (en) | 2008-04-01 |
| WO2002053558A1 (en) | 2002-07-11 |
| JP4031363B2 (ja) | 2008-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY27109A1 (es) | Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b | |
| ECSP055671A (es) | Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa | |
| UY27336A1 (es) | Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6 | |
| UY28946A1 (es) | Compuestos de aril-y heteroaril-alquilanina que contienen pirazol, composiciones farmacéuticas que contienen los compuestos y nuevos productos químicos intermedios | |
| UY27760A1 (es) | Nuevos derivados de pirrolidinio. | |
| UY28514A1 (es) | Nuevos compuestos | |
| ECSP034444A (es) | Derivados de 4-amino-6-fenil-pirrolo(2,3-d)pirimidina | |
| AR048642A1 (es) | Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento | |
| UY28150A1 (es) | Agentes terapeuticos | |
| CL2003002770A1 (es) | Compuestos derivados de pirrol e imiddazol; composiciones farmaceuticas que los contienen; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de enfermedades que estan asociadas con la modulacion de los receptores a canabinoides | |
| UY27851A1 (es) | Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso. | |
| AR032136A1 (es) | Compuestos espiroheterociclicos utiles como inhibidores reversibles de cisteina-proteasas | |
| SV2008001369A (es) | Benzimidazoles | |
| SV2003000925A (es) | Derivados espirotriciclicos nuevos y su uso como inhibidores de fosfodiesterasa-7 | |
| PA8468401A1 (es) | Compuestos para el tratamiento de la isquemia | |
| UY28342A1 (es) | Nuevos compuestos | |
| AR028948A1 (es) | Compuestos novedosos | |
| UY27388A1 (es) | Nuevos compuestos | |
| ECSP099394A (es) | Derivados de quinuclidinol como antogonistas de receptores muscarínicos | |
| BR0206595A (pt) | Composto, composição farmacêutica, e uso de um composto | |
| GT200900026A (es) | Derivados de 5,6 -bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii | |
| UY28536A1 (es) | Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos. | |
| PA8587501A1 (es) | Benzoxazinonas sustituidas y usos de las mismas | |
| UY29234A1 (es) | Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones. | |
| UY28356A1 (es) | Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20141111 |